V 19Alternative Names: V19
Latest Information Update: 22 Aug 2002
At a glance
- Originator GLYCODesign
- Class Antithrombotics
- Mechanism of Action Thrombin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 22 Aug 2002 Discontinued - Phase-II for Thrombosis in USA (unspecified route)
- 13 Sep 2000 No-Development-Reported for Thrombosis in USA (Unknown route)
- 30 Dec 1998 Phase-II clinical trials for Thrombosis in USA (Unknown route)